Skip to main content
. 2019 May 24;20(10):2560. doi: 10.3390/ijms20102560

Figure 1.

Figure 1

Anti CTLA-4 (such as Ipilimumab) increased the T-cell activation by binding the CTLA-4 receptor. Anti PD-1 (such as Nivolumab) and anti PD-L1 (such as Atezolizumab) allow the T-cell to identify the tumor cells binding to PD-1, or PD-L1, respectively.